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1. Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide and accounts for approximately 650,000 new diagnoses and 350,000 cancer 
deaths every year (Parkin, et al., 2005). In the United States, HNSCC accounts for 
approximately 5% of all cancer cases diagnosed per year. Even with significant advances in 
operative skills such as reconstructive microvascular free tissue transfer, and in adjuvant 
therapies such as hyperfractioned radiotherapy and concomitant chemoradiation, the 5-year 
survival of the HNSCC has not been markedly improved in the past three decades. The 
number of annually diagnosed cases amounts to over 42,000 individuals and results in more 
than 12,000 deaths per year in the United States. As is known, HNSCC is a locoregional 
disease notoriously for regional and distant metastases, representing the leading cause of 
death in HNSCC patients. Although surgical resection of isolated metastases is beneficial for 
some patients, the overall efficacy of surgery, chemotherapy or radiotherapy is still limited. 
The main reason for the poor 5-year survival may be that the most important prognostic 
factors for these patients are not only local control, but regional and distant metastases as 
well.  
2. Development of metastasis 
Metastasis is defined as the spread of disease from one organ or part to another not directly 
connected with it through the blood, lymph, or serosal surfaces. Recent investigations 
disclose the mysterious aspects of the cancer metastasis. The development of metastasis of 
tumor is a multi-step process, in which multiple genes participate in and play different 
roles. With regard to the regional lymph node metastasis, several important gene proteins 
related to mirovascular angiogenesis and lymphogenesis function as promoters of regional 
lymph node metastasis. For the regional metastasis to occur, it is necessary for tumor cells to 
enter the microvessels to gain the pathway to the lymphatic channels. After entering the 
tumor-draining lymphatic channels, the tumor cells migrate to the regional lymph nodes in 
the neck, in which they settle and form the foci of micrometastasis. In the event of distant 
metastasis, several processes determine the tumor spreading to other organ systems, 
including angiogenesis, tumor invasion into local stroma and vascular system, circulation of 
tumor cells, arrest of tumor cells at distant site, and colony formation at secondary site. It is 
obvious that tumor invasion into stroma and vascular system is a prerequisite to the 
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development of distant metastasis, which involves attachment of tumor to the basement 
membrane, degradation of extracellular matrix components, migration of malignant cells to 
the stroma and ultimate invasion to the surrounding blood vessels or lymphatic channels. 
Recently, results from several studies indicate that the disseminated cancer cells alter their 
adjacent stroma into a ‘‘metastatic’’ microenvironment that is similar to the primary tumor 
microenvironment in which they can survive and proliferate. A better understanding of the 
gene expression pattern and molecular biologic mechanisms of metastasis in HNSCC may 
be beneficial for exploration of new effective therapies to prevent the development of 
metastasis and to improve the survival of these patients. 
2.1 Genes involved in metastasis 
Development of metastatic carcinoma is associated with masses of molecules involved in 
cell adhesion, migration, and invasion in HNSCC. Further insight into the molecular basis of 
metastasis in HNSCC could lead to advances in screening, diagnosis, and treatment with 
improved clinical outcome. Multiple gene products are involved in angiogenesis, all of 
which have been demonstrated to be critical for regulating angiogenic phenotype. This has 
raised the need for comprehensive analysis of the angiogenic phenotype using microarray 
analysis and global proteomic approaches. Complex interplay between positive and 
negative regulators determines the degree of neovascularization in and around the tumor. 
And now emerging evidence suggests that the lymphangiogenic factors may also play 
important roles in lymph node metastasis in many cancers. 
2.1.1 Vascular endothelial growth factor (VEGF)  
As a key regulator of angiogenesis, the role of VEGF has been extensively studied. Tumor 
cells enter the circulation by penetration through proliferating capillaries that have 
fragmented basement membrane. Further progress in this multi-step cascade is controlled 
by the positive and negative regulators of angiogenesis. Recent studies have shown that 
VEGF receptor-expressing cells from the bone marrow arrive at a specific site of future 
metastasis even prior to arrival of metastatic cells (Ellis, 2008). First and foremost, VEGF is a 
highly potent angiogenic agent that acts to increase vessel permeability and enhance 
endothelial cell growth, proliferation, migration and differentiation (Johnstone & Logan, 
2007). In addition, VEGF promotes angiogenesis in many different tumor types. VEGF levels 
may affect tumor growth, metastatic potential, and response to radiotherapy. VEGF 
expression may prove to be an important prognostic factor in head and neck cancer (Smith, 
et al., 2000); VEGF positivity is the most significant predictor of poor prognosis. 
Accordingly, the potent role of VEGF in angiogenesis has spurred interest in using this 
molecule as a therapeutic target in antiangiogenetic therapy.  
2.1.2 Matrix metalloproteinases (MMP)  
As is known, MMP has the ability to degrade connective tissues such as the basement 
membrane, which is a crucial step in the initiation of metastatic process, thus serving as a 
positive regulator of metastasis. Expression levels of molecules involved in tissue 
remodeling and extracellular matrix (ECM) adhesion, especially MMP-1 and integrin-3, can 
provide an accurate biomarker system for predicting the risk of cervical lymph node 
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metastasis in oral squamous cell carcinoma (Nagata, et al., 2003). In order to breech the 
basement membrane and invade the connective tissue stroma, HNSSC must produce 
enzymes capable of degrading the extracellular matrix. General classes of these proteolytic 
molecules include MMPs, named for their dependence on Zn2+ as a catalyst, and the 
plasminogen activators. The MMPs are a large group of secreted proteinases that require 
zinc for catalytic activity. MMP-2 and MMP-9 are the largest members of this gene family. 
They are able to degrade connective tissue, among other substrates, the basement membrane 
collagen, which appears to be very crucial in tumor cell invasion and in the process of 
metastasis. 
The association of the expression of MMP-9 and MMP-2 with mode of tumor invasion and 
nodal involvement has previously been found in squamous cell carcinoma, and recently its 
utility has been proven in oral cancers (Miyajima, et al., 1995, Patel, et al., 2007). However, 
some studies have shown that the activation of MMP-2 was more prominent as compared 
with MMP-9 in malignant oral SCCs. Elevated activation ratio of MMP-2 has also correlated 
significantly with lymph node metastasis in oral SCCs. Accordingly, MMP-2 was considered 
by some investigators as more selective molecular marker for prediction of metastatic 
potentials of oral SCCs (Patel, et al., 2007). Certain other studies have shown results favoring 
the use of MMP-9 as a prognostic indicator (Ruokolainen, et al., 2004). Association between 
MMP-9 and vascular endothelial growth factor expression or micro vessel density has been 
found in head and neck carcinoma (Riedel, et al., 2000). The summary of MMPs produeced 
by HNSCC is illustrated in table 1. 
 
MMP        Name    Substrate 
Collagenases 
MMP-1 
              
MMP-8 
MMP-12 
MMP-13 
 
Interstitial 
collagenase 
Neutrophil 
collagenase 
Metalloelastase 
Collagenase3 
 
Collagens I, II, III, V, IX 
Collagens I, II, III, V, IX 
Elastin 
Collagen III 
Stromelysins 
MMP-3              
MMP-7 
MMP-10 
MMP-11 
 
Stromelysin 1 
Matrilysin   
Stromelysin 2 
Stromelysin 3 
 
Proteoglycans, collagen IV, gelatins 
Fibronectin, collagen IV 
Proteoglycans, collagen IV, gelatins 
Laminin and fibronectin 
Gelatinases 
MMP-2              
MMP-9 
 
Gelatinase A 
Gelatinase B 
 
Gelatin, collagens IV and V 
Gelatin, collagens IV and V 
Table 1. MMP produced by HNSCC 
2.1.3 Endostatin 
Endostain exhibits specific inhibitory action on the proliferating endothelial cells of newly 
formed blood vessels, representing one of the better defined and most potent negative 
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regulators of angiogenesis (O'Reilly, et al., 1997). Earlier studies have shown that plasma 
levels of endostatin in patients with HNSCC have been associated with histologic grade, 
recurrence, and survival rate (Homer, et al., 2002). However, the immunohistochemical 
expression of endostatin and collagen XVIII in SCC tissues and their significance for the 
growth and metastatic potential of these tumors have not been widely studied. In a recent 
study, the levels of endostatin were lower in the primary tumors of cases with multiple 
metastatic lymph nodes compared with non metastatic tumors. The differences in 
endostatin expression between these tumors corresponded well with the levels of collagen 
XVIII, suggesting that the reduction in endostatin expression in the node positive group is 
because of decreases in the production of the precursor molecule collagen XVIII. On the 
other hand, these results contradict with those of Homer et al (Homer, et al., 2002), who 
observed a positive trend between higher levels of endostatin and nodal metastasis and an 
association between increased endostatin expression and higher tumor grade, recurrence, 
and death in patients with HNSCC. The authors attributed this discrepancy to differences in 
methods used, as these investigators measured the circulating levels of endostatin, whereas 
this study assessed the levels in tissue samples (Nikitakis, et al., 2003).  
2.1.4 Others 
E-cadherin is an important molecule that promotes cell to cell adhesion which serves as a 
positive regulator of metastasis. Low expression of E-cadherin should be considered as a 
high-risk group for late cervical metastasis when a wait-and-see policy for the neck is 
adopted (Lim, et al., 2004). The plasminogen activators (PAs) are another class of proteases 
that have been confirmed to play important parts in invasion and metastasis of HNSCC. 
PAs are neutral serine proteases which catalyze the synthesis of plasmin from plasminogen. 
Plasmin is a fibrinolytic enzyme, also active in degrading type IV collagen and laminin. 
2.2 Molecular pathologic changes during development of metastasis 
HNSCC will progress from carcinoma in situ, to microinvasive carcinoma, to an invasive 
tumor with stromal invasion, and to a deeply invasive tumor with lymphatic metastasis. 
The essential element in the transition from carcinoma in situ or preinvasive to invasive 
carcinoma is the destruction of the underlying basement membrane.A reasonable 
interpretation of these studies is that increased degradation of basement membrane 
correlates with increased invasion and metastasis. Adherence to the basement membrane 
and extracellular matrix components is another method by which tumor cells can facilitate 
local invasion and metastasis. Alterations in tumor cell adherence and the expression of 
these cell surface ligands may facilitate invasion, metastasis, and neovascularization. 
2.2.1 Detachemnt and migration of tumor cells 
Essential characteristics of cancer are the ability to invade surrounding tissues and 
metastasize to regional and distant sites. The events attendant to local invasion by an 
epithelial tumor include loss of adhesion to surrounding tumor cells and basement 
membrane, production of enzymes and mediators which facilitate the incursion of 
malignant cells into the subjacent connective tissue. Therefore, the late stages of cancer 
involve progressive tumor invasion and metastasis, which are the stages that ultimately 
affect vital functions and cause death in patients. Many important histopathologic and 
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molecular events associated with tumor progression and metastasis. Development of 
invasive carcinoma is associated with focal dissolution of the basement membrane and 
extracellular matrix (ECM), detachment, and migration of cells into the submucosal tissue. 
HNSCCs that exhibit a streaming pattern of small clusters of cells through the ECM are 
associated with more aggressive behavior and poor prognosis. HNSCCs exhibit alterations 
in expression of a repertoire of cell adhesion molecules and ECM substances that function in 
attachment and migration. 
2.2.2 Angiogenesis 
In 1972, Folkman first articulated the hypothesis that tumor growth was angiogenesis-
dependent. Characteristics of prevascular tumors include a linear growth phase, absence of 
intratumoral vessels, and size limited to < 1 mm3. Once tumors become vascularized, 
obtaining nutrients and exchanging metabolic waste products with the host become more 
efficient and the growth properties of the tumor change. Characteristics of tumors in the 
'vascular phase' are histological demonstration of intratumor capillary networks, size> 1 mm3, 
and an exponential growth phase (Folkman, 1990, 1992). Tumor progression to a size that 
becomes visible and has an effect on adjacent structures requires an increase in supply of 
oxygen and nutrients and removal of waste, which implies that new blood vessel formation is 
critical in cancer progression (Folkman, 1996). Enlargement of tumors to a size beyond 0.5 cm 
exceeds the range for diffusion of oxygen from existing vessels and necessitates new blood 
vessel formation, called neoangiogenesis. Angiogenesis is increased in various human cancers, 
including HNSCCs, and correlates with tumor progression and metastasis. Vascular 
endothelial growth factor (VEGF) has been shown to be a key regulator of angiogenesis.  
The ability to stimulate new blood vessel growth (neovascularization or angiogenesis) is an 
integral part of organogenesis, reproduction, and wound healing and repair, and in this 
context it is short term and self-limiting. Pathologic angiogenesis is not autoregulated and 
results from alterations in growth control, which are parts of particular disease processes. 
However, the ability of a tumor to stimulate an angiogenic response should directly 
determine the capability of a tumor to metastasize and ultimately kill the host. The evidence 
regarding microvessel density as a predictor of nodal metastasis, or response to treatment in 
HNSCC remains conflicting, furthermore initially good correlations between microvessel 
density and outcome recently being challenged. Tumors invade local connective tissues by 
the production of proteinases and the expression of cell surface markers which facilitate 
attachment to components of the extracellular matrix. Tumor size is limited by the diffusion 
of nutrients from adjacent blood vessels, however, tumors circumvent this limitation by 
recruiting host capillaries to form an intratumor blood supply.  
2.2.3 Lymphoangiogenesis 
Lymphangiogenesis is associated with locoregional disease recurrence in early-stage oral 
carcinoma (Munoz-Guerra, et al., 2004). The presence of intratumoral lymphangiogenesis is 
a useful discriminator in predicting the outcome of patients with absence of lymph node 
metastasis. Various studies has stressed on the impact of tumor thickness as a significant 
factor that had predictive value for local disease recurrence, survival and neck metastasis. 
The rationale was that the depth of invasion would determine proximity to blood and 
lymphatic vessels and facilitate the ability of the tumor to expand. In most cases, metastasis 
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in squamous cell carcinoma occurs via the lymphatic vessels and dilation of lymphatic 
vessels is frequently found in oral tumors with lymph node involvement. However, the 
influence of intratumoral or peritumoral lymphangiogenesis on squamous cell carcinoma of 
the oral cavity is still controversial. 
Several markers have been utilized in the study of lymphangiogenesis. The main 
disadvantage of this method is that it relies on quantitative rather than qualitative 
differences between lymphatic and blood vessels and therefore requires a certain amount of 
subjective interpretation. In addition, most antibodies used react with both blood vessels 
and lymph vessels (Hannen & Riediger, 2004). Some of these studies have correlated the 
presence of VEGF-C in the tumor cells with an increased likelihood of lymph node 
metastasis in oral SCC, which seems promising (Kishimoto, et al., 2003, Shintani, et al., 2004, 
Warburton, et al., 2007). An association between lymphangiogenic growth factors, 
intralymphatic growth and tumor metastasis has been suggested. However, the role of 
intratumoral lymphangiogenesis in the progression of squamous cell carcinomas has not 
been studied. Tumor invasion of capillaries and lymphatics leads to dissemination of tumors 
and the establishment of histologically identical tumors at secondary sites. 
2.2.4 Cellular components of tumor microenvironment 
It has been shown that during progression, squamous cell carcinomas undergo additional 
changes needed for growth and metastasis that depend on the host (Chen, et al., 1997). 
Inflammatory cells infiltrating squamous cell carcinomas are one of the host components 
that promote growth and metastasis. New vessel formation is commonly associated with an 
increase in inflammatory cells. Growth of the tumor epithelia and angiogenesis is also 
accompanied by increased infiltration of inflammatory cells and proliferation of fibrous 
stroma. These inflammatory cells bear a stem cell marker called CD34 and appear to 
differentiate into granulocytes and endothelial cells that form new blood vessels. 
Granulocytes have been found to promote growth and metastasis. Granulocytes from the 
host can release growth factors and proteases that stimulate growth and invasion of tumor 
cells. Several studies have suggested that tumor cells capable of inducing host inflammatory 
and stromal cell responses grow, invade, and metastasize more rapidly.  
Squamous cell carcinomas also induce proliferation of stromal fibroblasts. Fibroblasts also 
secrete factors and ECM substances that can promote growth. The establishment of 
metastases requires cell arrest and vessel formation in a new location. HNSCC shows a 
predilection for metastases to the lymphatics, lungs, liver, and bone marrow, suggesting that 
the cells and substrate of the reticuloendothelial system provide a favorable environment for 
arrest and formation of squamous cell carcinoma metastases. Non-malignant cells within the 
tumor microenvironment also play important roles in modulating tumor progression and 
metastases. Functional studies have identified several tumor-promoting functions for 
macrophages in primary tumors. These include promotion of angiogenesis, tumor cell 
invasion, migration and intravasation. 
Local tissue invasion and migration into the subjacent connective tissue matrix by HNSCC 
are dependent of the production of cell surface molecules, enzymes and motility factors. In 
addition to the production of these locally active molecules, HNSCC produces growth 
factors or cytokines which target other cell types. Cytokines are low molecular-weight 
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proteins which affect cell-cell communication and signal cellular proliferation, 
differentiation, activation, and migration.  
3. Biological processes of the metastatic cascade 
Tumor metastasis is ultimately the result of an imbalance between forces favoring and 
opposing the development of secondary tumors. The first steps in the development of 
distant metastases involve (1) the initiation of the primary tumor in a genetically susceptible 
host, (2) the promotion and progression of malignant cell gene mutations favoring clone 
expansion, and (3) uncontrolled proliferation of these malignant clones of cells due to the 
actions of autocrine growth factors and growth factor receptors.  
The risk of distant spread is related to primary tumor site, its local and regional extension, 
and the phenotype (Li, et al. 2009). Distant metastases are particularly important in 
supraglottic laryngeal and pharyngeal cancers (Buckley, 2000). Factors which favor the 
development of metastases include the primary tumor’s ability to activate oncogenes, 
downregulate tumor suppressor genes, express cell-surface adhesion molecules, synthesize 
and respond to autocrine and paracrine growth and motility factors, secrete proteases, and 
produce angiogenic and immunosuppressive cytokines. Factors opposing the development 
of metastases include activated tumor suppressor and antimetastasis genes, enhanced host 
immune responses, synthesis of protease and angiogenesis inhibitors by both the tumor and 
the host, and anatomic and structural barriers. All of these phenomena are the result of 
multiple gene mutations culminating in the development of secondary tumors at distant 
sites. 
Fidler and colleagues (Fidler & Hart, 1982) articulated the principal of tumor heterogeneity, 
which is now widely accepted. The development of local-regional and distant metastases 
begins with the initiation of the primary tumor and ends with the establishment of 
metastatic clones throughout the host. Several processes including the differential 
expression of cell adhesion molecules, release of metalloproteinases, and angiogenesis occur 
at multiple points in the metastatic cascade. This cascade involves an sequential process 
including tumor invasion into local stroma and vascular system, circulation of tumor cell 
and arrest at the distant site, and clonal formation at secondary site. 
3.1 Invasion into local stroma and vascular system 
The process of tumor invasion involves attachment of the tumor to the basement membrane, 
degradation of extracellular matrix components, and migration of the malignant cells into 
the surrounding stroma. We will refer again the process when we consider the 
establishment of the tumor at a secondary (distant) site.  
3.2 Circulation of the tumor and arrest at the distant site 
Metastatic tumors, regardless of how they exist in the circulation, will establish distant 
metastases either by mechanical impaction or attachment to the endothelial cell surfaces. 
Mechanical impaction of the tumor/lymphocyte/platelet emboli will occur when the 
diameter of the embolus approaches that of the vessel. The tumor will then adhere to the 
lumen surface of endothelial cells and begin to grow. The second mechanism is the 
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attachment of single tumor cells to the exposed basement membrane on the subendothelial 
side of the capillary lumen. 
3.3 Colony formation at the secondary site 
The common theoretical mechanisms exist for determining the locations of distant 
metastases were first articulated by Fidler as the 'seed and soil hypothesis' of tumor 
metastasis. These mechanisms include: (1) tumor metastasis equally to all organs, but 
preferentially only grow in locations which provide appropriate growth factors (soil); (2) 
circulating tumor cells have receptors specific for the endothelial cells of only certain target 
organs (seed), and (3) circulating tumors have receptors for specific chemotactic factors 
produced by the target organ. These factors result in the preferential attraction of the tumors 
to the target organ (seed soil) (Markus, 1988). 
4. Lymph node metastasis of HNSCC 
The status of the regional lymphatics is one of the most important prognostic indicators in 
patients with head and neck cancer. HNSCCs that are localized to the primary site without 
regional lymph node metastasis have excellent cure rates with either surgery or radiation 
therapy. The presence of regional metastases results in cure rates that are approximately half 
of those obtainable if metastasis to the regional lymphatics is not present. Thus the 
treatment of the neck has become one of the most actively debated topics in the field of head 
and neck oncology. 
4.1 Patterns  
The primary sites for HNSCC are mainly in the oral cavity, oropharynx, hypopharynx and 
larynx. In 1972, Lindberg published the location of nodal metastases in patients with 
squamous carcinoma of the upper aerodigestive tract as determined by clinical examination 
(Lindberg, 1972). This review consisted of 2,044 previously untreated patients with HNSCC. 
The presence of nodal metastasis and its location was assessed and correlated with the 
location and stage of the tumor at the primary site. Primary sites were divided into oral 
tongue, floor of mouth, retromolar trigone/anterior faucial pillar, soft palate, tonsillar fossa, 
base of tongue, oropharyngeal walls, supraglottic larynx, hypopharynx and nasopharynx. 
Fifty-seven percent of patients presented with clinical evidence of metastasis in the cervical 
nodes. Lindberg showed that for lesions of the oral tongue, floor of mouth, retromolar 
trigone/anterior faucial arch and soft palate, the incidence of cervical nodal metastasis 
increased with the size of the primary tumor. However, the incidence of nodal metastasis 
did not correlate with the size of the primary in tumors of the tonsillar fossa, base of tongue, 
supraglottic larynx, and hypopharynx. 
Clinicopathological studies on the specimens from surgical removal of primary tumors and 
the associated treatment neck dissection tissues revealed patterns and impacting factors of 
cervical lymph node metastasis in HNSCC (Li, et al., 1996). For oral cavity cancers, the most 
common neck regions for neck node metastasis are level I to level III. Whereas, cervical 
lymph node metastasis from the cancers of oropharynx, hypopharynx and larynx are most 
frequently found in level II to level IV. Lindberg demonstrated that squamous cell 
carcinomas of the upper aerodigestive tract tend to metastasize to the neck in a predictable 
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pattern. By far, the most common site of metastasis by all tumors is to the ipsilateral level II 
nodes. Tumors that lie within the oral cavity anterior to the circumvallate papillae have a 
propensity to metastasize to levels I through III, with levels IV and V seldom involved. 
Tumors of the oropharynx have a low propensity to metastasize to level I; metastasis is most 
common to level II with decreasing incidence of metastasis in levels III and IV. These tumors 
have a higher rate of metastases to level V than oral cavity tumors but the rate is still low. 
Tumors of the supraglottic larynx and hypopharynx rarely metastasize to level I, again 
metastases were most common to level II with a decreasing incidence in levels III and IV 
and metastases to level V were infrequent. Contralateral metastases were uncommon in 
cancers of the floor of mouth, oral tongue, hypopharynx, and retromolar trigone/anterior 
faucial arch. In contrast, tumors of base of tongue, oropharyngeal walls, soft palate, 
supraglottic larynx, and tonsil have substantial rates of contralateral metastases. 
Lindberg’s data clearly showed that in cases of squamous cell carcinoma of the upper 
aerodigestive tract, with the exception of nasopharyngeal carcinoma, nodal metastasis 
occurs in a predictable pattern and it may, in certain instances, be sound to exclude 
dissection of the level V lymph nodes. However, this study provides only information on 
clinically positive nodal metastasis—it provides no information on the incidence and 
location of occult nodal metastasis. Such information on microscopic metastasis can only be 
obtained from a surgical specimen. Byers and colleagues published one such study (Byers, 
et al., 1988) in 1988. They examined the specimens of 428 patients undergoing 648 modified 
neck dissections and correlated the location of the pathologically positive lymph nodes with 
the primary site. The majority of these neck dissections were selective neck dissections and 
therefore not all of the lymph node levels at risk were examined in each patient. This study 
essentially confirms the clinical data of Lindberg (Lindberg, 1972) that lesions anterior to the 
circumvallate papillae are most likely to metastasize to lymph nodes levels I through III and 
lesions within the hypopharynx and larynx to levels II through IV. It must be pointed out, 
however, that the majority of these dissections were less than comprehensive and therefore 
the low incidence of metastasis to certain nodal levels may simply reflect the lack of 
sampling of those levels. 
In order to fully assess all the lymph node levels at risk for a particular primary site, surgical 
specimens should include all lymph node levels (comprehensive neck dissection). Just such 
information is provided in a series of studies by Shah and colleagues, (Candela, et al., 1990, 
Candela, et al., 1990, Shah, et al., 1990) which involved 1,081 previously untreated patients 
who underwent 1,119 classic RNDs for squamous carcinoma of the upper aerodigestive 
tract. The operations consisted of 343 elective RND in the clinically N0 setting and 776 
therapeutic RND in the clinically N+ setting. In patients with primary tumors of the oral 
cavity undergoing therapeutic RND, the majority of metastatic nodes were located in levels I 
to III; level IV was involved in 20 percent of specimens and level V in only 4 percent. In 
those with primary oropharyngeal tumors, the majority of metastases were located in levels 
II to IV; levels I and V were involved in 17 percent and 11 percent of the specimens 
respectively. Therapeutic neck dissection in hypopharyngeal tumors showed that the 
majority of metastases were located in levels II to IV, while levels I and V were involved in 
10 percent and 11 percent of the specimens, respectively. Primary tumors of the larynx 
metastasized to levels II through IV with levels I and V being involved in 8 percent and 5 
percent of the specimens, respectively. 
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In the setting of elective RND in patients with primary tumors of the oral cavity, the 
majority of metastases were located in levels I to III; levels IV and V were involved in 9 
percent and 2 percent of the specimens, respectively. In patients with primary tumors 
located in the oropharynx, the majority of metastases were located in levels II to IV; levels I 
and V were involved in 7 percent of the specimens. Patients with tumors of the 
hypopharynx undergoing elective RND had the majority of metastases in levels II to IV, 
while levels I and V were not involved in any of the specimens. Primary tumors of the 
larynx metastasized primarily to levels II through IV, while levels I and V were involved in 
14 percent and 7 percent of the specimens, respectively. O'Brien et al.(O'Brien, et al., 2000) 
found occult metastatic disease in 30% of patients, and Lim et al (Lim, et al., 2006, Lim, et al., 
2006) found it in 28%. 
The question of metastasis to level V was addressed by another study by Davidson and 
colleagues. (Davidson, et al., 1993) They examined the specimens of 1,123 patients 
undergoing 1,277 RNDs and found metastases to level V in only 3 percent of patients. Level 
V metastases were highest in patients with hypopharyngeal and oropharyngeal primary 
sites (7% and 6% respectively). Only 3 of the 40 patients with level V metastases had these in 
the face of a clinical N0 stage. They concluded that the incidence of metastases to level V 
was small in general, and extremely unlikely in the clinically N0 patient.  
4.2 Risk factors 
Clinicopathologic factors associated with the development of cervical lymph node 
metastasis have been well studied for other locations like tongue, mouth floor, and cheek, in 
particular concerning tumor size (in tongue carcinoma≥3 mm), tumor depth (≥4 mm in 
tongue carcinoma), differentiation, mode of invasion, microvascular invasion, and histologic 
grade of malignancy (Kurokawa, et al., 2002, Sparano, et al., 2004, Wallwork, et al., 2007). 
The presence or absence of lymph node metastasis is a major prognostic factor for survival 
in patients with negative cervical lymph nodes (Hiratsuka, et al., 1997). A high incidence 
(20–30%) of cervical metastasis of cancer in the tongue/mouth floor has been well studied 
(Kurokawa, et al., 2002, Sparano, et al., 2004, Wallwork, et al., 2007). But very few studies 
have been performed concerning squamous cell carcinoma of the maxilla (Simental, et al., 
2006). Sparamo et al(Sparano, et al., 2004) and Kruse et al (Kruse & Gratz, 2009) reveal that 
the higher the grading, the higher the risk of cervical metastasis. Therefore, regarding the 
proportion of late cervical metastasis, the question arises whether an elective neck dissection 
should be provided in early-stage squamous cell carcinoma. Capote et al. (Capote, et al., 
2007) reported that in pT1N0 and pT2N0 oral squamous cell carcinoma, neck dissection 
therapy was a significant prognostic factor for recurrence and survival. Therefore, tumor 
size, tumor depth, and differentiation should be taken into consideration for the planning of 
neck dissection for squamous cell carcinoma of the upper jaw. Also the mode of invasion 
plays an important role in therapy planning because in certain localizations like the palate, 
the tumor does not need to invade very deeply before reaching the bone.  
4.3 Prognostic factors 
As an independent prognostic factor, cervical lymph node metastasis has a great impact on 
disease-free and overall survival of patients with HNSCC. Among various 
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clinicopathological factors, the most important prognostic factors are pN+, numbers of 
positive node (more than 3 positive nodes), lower level of invasion, and especially the 
extracapsular nodal spread (ECS) (Di, et al., 2009). A review of literature reveals the impacts 
of clinicopathological factors on neck recurrence. For example, if residual disease after neck 
dissection, 2 or more pathologic lymph nodes, extracapsular spread (ECS), more than 3 cm-
diameter pathologic lymph node and invasion of soft tissue are found in neck dissection 
specimens, the risk of neck recurrence is considered to be high (Li, et al., 2009). Since 
treatment neck dissections for HNSCC vary from selective neck dissection (SND) to radical 
neck dissection (RND), it is necessary to analyze the clinicopathologic risk factors for 
regional recurrence in a group of positive-node patients treated with such neck dissections 
and postoperative radiotherapy (PORT) in order to determine which patients need further 
adjuvant therapy and further short-interval follow-up. However, the majority of the 
literatures draw these conclusions in the absence of adjuvant radiotherapy. Furthermore, 
some reports show that these factors have no statistical significance in predicting regional 
failure following neck dissection and adjuvant PORT. It is now well established that the 
development of cervical metastases, in particular those with extranodal extension of tumor, 
negatively impacts both regional control and survival of patients with laryngeal carcinoma 
(Myers & Fagan, 1999).  
4.4 Modern concepts in management of cervical lymph node metastasis in HNSCC 
The lymphatic system of the head and neck is complicated (Fisch, 1964). An extensive 
analysis of 2044 medical records of patients with HNSCC who had not received prior 
treatment led Lindberg to divide nine lymph node regions on each side and, additionally, 
the parited lymph nodes (Lindberg, 1972). The lymph fluid of the upper aerodigestive tract 
is drained via about 300 regional cervical lymph nodes, which are divided according to the 
current classification established by Robbins (Robbins, et al., 2002) into nine lymph node 
levels (level I–VI). It is well understood that an incomplete surgical resection margin is the 
most important single factor for tumor recurrence, which is determined not only by the 
experience of the surgeon but also by the limitation of surgical excision. For example, if 
multiple nodes or ECS of neck diseases are present, it may be difficult to obtain adequate 
surgical resection margins or to resect all metastatic lymph nodes in the neck. Recurrence in 
the neck is more likely to occur in patients with these neck situations. For this reason, it is 
widely accepted that ECS is a marker for biologically aggressive disease and patients with 
HNSCC who have evidence of ECS need aggressive multimodality therapies including 
surgery, PORT and, even chemotherapy. 
4.4.1 Detection of lymph node metastasis 
Most tumors of the head and neck initially metastasize to the regional lymph nodes. The 
presence of cervical metastases is the most significant oncological factor in the prognosis of 
HNSCC (SCC) because early detection and treatment may prevent distant metastases (Gray, 
et al., 2000). The assessment of cervical lymph nodes is known to be extremely difficult 
clinically. Despite recent advances in the fields of radio diagnosis, its utility to detect occult 
neck metastasis still lacks considerable power. Owing to the high number of undersized 
lymph node metastases, the non-invasive neck staging methods are limited to a maximum 
accuracy of 76% (Stuckensen, et al., 2000). Pre-surgical staging of the neck has become more 
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complex over the years. Clinical assessment of the neck by palpation, while providing 
critical information, is inadequate in its sensitivity for detecting metastatic disease to the 
cervical nodes. Error rates as high as 40 percent have been reported when physical 
examination alone is used to evaluate the neck (Teichgraeber & Clairmont, 1984). Patient 
factors such as a short, obese neck, as well as prior irradiation play a role in decreasing the 
accuracy of this technique. Clearly, radiologic assessment of the neck adds to the sensitivity 
and specificity of preoperative neck evaluation. 
4.4.1.1 Comouterized tomography (CT) and magnetic resonance imaging (MRI) 
Computerized tomography (CT) and magnetic resonance imaging (MRI) have become the 
workhorses of imaging modalities in HNSCC. Size criteria are frequently used as indicators 
of metastatic involvement. Other features such as central necrosis or ring-enhancement aid 
in specificity but are relatively infrequent findings. Generally, a subdigastric node 
measuring > 15 mm, a submandibular node > 12 mm, and other nodes > 10 mm are 
suspicious for involvement. Using criteria such as these, the accuracy of detecting neck 
disease approaches 90 percent (John, et al., 1993). Size, however, is certainly not 
pathognomonic for cancerous involvement of lymph nodes. Even in the patient with an 
identified squamous cell carcinoma of the upper aerodigestive tract, a myriad of alternative 
causes of enlarged lymph nodes exist. Further, microscopic foci of disease may exist in 
nodes of normal size. As CT or MRI is often employed to evaluate the primary lesion, 
inclusion of the neck in the area of study incurs nominal additional expense and no 
morbidity. Although CT and MRI provide excellent anatomic detail and are the current 
modalities of choice, they provide little information on the biology of the lymph node. 
4.4.1.2 Positron emssion tomography (PET) 
Several studies have evaluated fluorodeoxyglucose (FDG) PET in this setting, attempting to 
identify the patients who need neck dissection. In 3 studies totaling 48 patients, in which a 
sentinel node biopsy with immunohistochemistry was used as the gold standard, the 
detection rate of PET was between 0% and 30%, making PET an unreliable modality in this 
clinical setting (Civantos, et al., 2003, Stoeckli, et al., 2002). This is not unexpected, given that 
40% of cervical nodal metastases are less than 1 cm in size and PET detection rate for nodes 
less than 1 cm is reported at 71% (Menda & Graham, 2005). Numerous promising pilot 
studies have evaluated sentinel node biopsy (SNB), up to 16% patients required additional 
immunohistochemistry (IHC) on the sentinel nodes to detect metastasis (Civantos, et al., 
2006). Owing to these inadequacies in detection of occult nodal metastasis, surgical 
dissection and serial histologic examination are the currently accepted "yardsticks". 
Another problem that should be considered seems to be the detection of micrometastasis. 
The assessment of the status of cervical lymph nodes is difficult, and therefore a treatment of 
patients with a clinical stage N0 neck is controversial. In most studies, the use of CT has an 
error rate ranging from 7.5 to 19%(van den Brekel, et al., 1990). In the late 1990s, the PET 
using F-18 FDG, a functional imaging methodology that provides information about tissue 
glucose metabolism, was applied. Consequently, a high FDG accumulation is manifested on 
PET images, but inflammation also reveals an increased FDG uptake and can lead to false-
positive results. On the other hand, low tumor metabolic activity, the presence of small 
lesions, and hypoglycemia can lead to false-negative results (Murakami, et al., 2007). 
Concerning cervical lymph nodes, Ng et al. (Ng, et al., 2005) reported that sensitivity and 
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specificity of PET images were 75% and 93%, respectively. Sigg et al. (Sigg, et al., 2003) 
reported a sensitivity of 93% and a specificity of 100%. PET together with CT images 
showed a 15% increase in the accurate identification of nodal staging over using the PET 
images alone (Jeong, et al., 2007). PET/CT seems to have a higher sensitivity and specificity 
for detecting lymph node metastasis (Leong, et al., 2006, Wild, et al., 2006).  
4.4.1.3 Ultrasound 
Due to its non-invasiveness and affordability, ultrasound (US) has been investigated as a 
potential tool in evaluating neck disease. Factors such as size, irregular margins, and echo 
characteristics of lymph nodes have been shown to have predictive value in assessing 
involved nodes. The overall sensitivity of this approach, however, is limited due to the 
operator-dependant nature of ultrasound.(John, et al., 1993) Some authors have proposed 
ultrasound in combination with ultrasound-guided fine needle aspiration as an approach to 
diagnosis. Takes and colleagues (Takes, et al., 1998) examined, with ultrasonography, 64 
necks staged N0 based on physical examination. Those with nodes greater than 5 mm in size 
underwent ultrasound-guided needle biopsy. Results were further verified with 
histopathologic examination and the findings compared with CT of the neck for detection of 
involved nodes. They found a 48 percent sensitivity, 100 percent specificity, and 79 percent 
accuracy for ultrasound versus 54, 92, and 77 percent respectively for CT. These results 
demonstrate that, in experienced hands, ultrasound can be a useful tool. Its widespread 
application, however, is limited by the technical expertise required for accurate 
interpretation. 
4.4.2 Management 
4.4.2.1 General principles 
The type, grade, site and stage of the primary tumor determine the risk of cervical 
metastases and hence the type of treatment modality. Treatment of the neck in patients with 
clinical evidence of nodal metastasis has traditionally been surgical. In recent decades, this 
has been extended to include a combination of surgery and radiation therapy. The role of 
chemotherapy in the management of neck disease remains controversial and is currently 
being actively investigated. In oral tongue carcinoma, the risk of neck metastasis is 
significantly associated also with the depth of tumor invasion (Pentenero, et al., 2005). The 
patterns of spread of cancer to cervical lymph nodes are predictable, based on the 
anatomical location of the primary tumor. Therefore, in the absence of clinical evidence of 
neck disease, the pathological features of the primary tumor along with its site of origin and 
clinical T stage are used to stratify the risk of positive neck metastases and, consequently, 
the need for a neck dissection. When the risk for positive neck lymph nodes exceeds 15–20%, 
elective neck dissection is indicated – not only as treatment but also to evaluate the need for 
adjuvant therapy. A selective neck dissection, directed to the basins at risk for lymphatic 
spread, is commonly used for this purpose. The presence of palpable neck disease mandates 
comprehensive clearance of the lymphatic basins in the neck. Radical neck dissection was 
considered the primary modality for treatment of HNSCC with clinical evidence of cervical 
metastases. However, sacrificing vital structures during radical neck dissection causes 
severe disabilities in patients and a markedly reduced quality of life. Advances in the 
anatomic elucidation of the neck, enhanced understanding of the biological behavior of 
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tumors, and improved surgical methods have contributed to the emergence of the functional 
neck dissection technique, resulting in excellent survival and functional outcome(Shah & 
Gil, 2009). Exact knowledge of the anatomy of the neck and its adjacent structures and the 
risk and location of common cervical metastases is essential for the operative treatment of 
HNSCC. 
Although primary tumor control is achievable in early tumors with minimally invasive 
surgery, such as transoral or robot-assisted procedures, the management of the neck is still 
an important consideration in the treatment of HNSCC. Surgical management of the neck in 
patients with pharyngeal cancers does not usually involve a dissection of the 
retropharyngeal lymph node (RPLNs). Neck dissections do not routinely address RPLNs, 
creating a potential for recurrence in the retropharynx and the need to address this nodal 
basin with radiotherapy (Tauzin, et al., 2010). Treatment of the neck in patients with clinical 
evidence of nodal metastasis has traditionally been surgical. In recent decades this has been 
extended to include a combination of surgery and radiation therapy. The role of 
chemotherapy in the management of neck disease remains controversial and is currently 
being actively investigated. 
4.4.2.2 Adjuvant therapy 
Although the practical value of postoperative radiotherapy (PORT) for improving survival 
in HNSCC is well acknowledged, it remains controversial whether this postoperative 
radiotherapy, an adjuvant treatment, could prevent recurrence in the neck in patients 
having ECS. Smeele et al. found that PORT dose of 62.5 Gy and more could increase neck 
control rates in patients with ECS treated with surgery and PORT for HNSCC. Peters et al. 
demonstrated that metastatic lymph nodes with ECS were adequately controlled by PORT 
at dosage of 63 Gy or more (Peters, et al., 1993). However, Prim et al. reported that the 3-
year recurrence rates in the neck were 10.7% in patients without ECS and 49.6% with ECS in 
squamous cell carcinoma of the larynx with pathologically proven lymph node metastasis, 
and PORT did not appear to improve the outcome (Prim, et al., 1999). Shingaki et al. found 
that PORT did not decrease the rate of neck recurrence in patients of oral cavity carcinomas 
with ECS (Shingaki, et al., 2003). These findings suggest that the exact value of PORT in 
controlling neck recurrence needs to be further documented and recommended for adjuvant 
chemotherapy. Our findings suggest that the presence of ECS remains a determined risk 
factor for neck recurrence after surgery and adjuvant PORT in N+ patients with HNSCC. 
There were no significant risk factors associated with regional failure in ECS- group. Except 
for PORT, no additional adjuvant therapy is required for N+ patients without ECS. 
However, more adjuvant therapies are to be considered after PORT in patients with ECS for 
the purpose of a more effective neck control. 
4.4.2.3 Scenario in the management of an N0 neck 
Due to the fact that the prognosis of patients suffering from squamous cell carcinoma of the 
upper aerodigestive tract depends significantly on the presence or absence of lymph node 
metastasis, the question of detecting clinically occult lymph node metastases is still 
important concerning the management of the clinical N0 neck. The published rate of lymph 
node metastasis depends on the location of the primary tumor, with values from 12% to 
over 50% (median, 33%) (Hosal, et al., 2000). Numerous authors favor elective treatment of 
the lymphatic region (neck dissection) if the presence of occult lymph node metastasis can 
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be expected with a probability of 20% or more. However, other authors prefer to adopt a 
“wait and see” strategy, although this requires both great compliance from the patient and 
great expertise on the part of the responsible physician to identify metastasis early. Another 
argument in favor of elective neck dissection versus a “wait-and-see” strategy is the 
significant deterioration of the survival rate when neck disscetion is due after clinical 
disease is detected (Godden, et al., 2002). 
Regarding the current scenario in the management of an N0 neck, there are presently three 
policies advocated, which include elective neck irradiation, prophylactic neck dissection or 
close observation. The choice of therapy often takes into consideration T stage, site of 
primary, grade, compliance for follow-up, or the probability for occult metastasis [>20%]. 
Treatment of the neck, even when included with the primary treatment, often confers 
additional costs, morbidity and prolonged treatment time to the patient. Most often, a single 
modality treatment is used to treat the primary site and neck. The choice of which is dictated 
by the treatment of the primary site. There is no conclusive evidence to show if this elective 
neck treatment approaches contribute to improved overall survival for the patients with 
HNSCC and clinically negative neck. 
4.4.2.4 Sentinel node and elective neck dissection 
The elective treatment of the regional lymphatic drainage can generally be performed either 
surgically or radiotherapeutically. The choice of one of these procedures generally depends 
on the therapy of the primary tumor. An advantage of elective neck dissection over 
radiotherapy is that the histological examination of the neck dissection specimen can give 
important information for deciding therapy, as well as about the prognosis. Thus, the 
sentinel node concept for squamous cell carcinomas of the upper aerodigestive tract is quite 
appealing. Furthermore, limits and pitfalls of SLNs for HNSCC discussed elsewhere 
illustrate that an advanced intranodal tumor growth with extracapsular metastatic spread, 
leads to a significant reduction of the radiotracer uptake (Dunne, et al., 2001). Even small, 
clinically unsuspected lymph nodes may reveal extracapsular tumor growth with resulting 
lack of radiopharmacon accumulation (Coatesworth & MacLennan, 2002). The dominating 
metastatic region of pharyngeal and laryngeal carcinomas is mainly level II and less 
commonly, level III. Carcinomas of the anterior oral cavity drain mostly into level I and less 
commonly into level II. Accordingly, neck dissection of these lymph node levels can be 
expected to include the majority of clinically occult metastases. With this background, it 
must still be clarified whether the intraoperative identification of the radiolabeled SLN is 
appropriate to reduce the extent of selective neck dissection in the suspected N0 neck, or 
whether neck dissection can be completely avoided in the case of histologically-proven 
tumor-free SLN. Opponents of such a procedure argue that  selective neck dissection 
already has a morbidity that must be considered. Supporters of sentinel lymphadenectomy 
stress both protecting the intact, i.e. non-metastatic, cervical lymph node systems and 
reducing the extent of surgery. Scarring contractures, paresthesia, and persisting lymph 
edemas can be reduced by a selective SLN dissection. Current research aims to optimize 
surgical access to the SLNs. The first results on endoscopically performed selective 
lymphadenectomy led to the assumption that this method of lymph node dissection could 
achieve some significance in the therapy of the clinical N0 neck, provided that it is based on 
the SLN concept (Werner, et al., 2004). 
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However, the techniques would have to be optimized. Furthermore, prospectively collected 
data should be gathered and analyzed. Within such an investigation, it would make sense to 
examine frozen sections of the excised lymph node. Depending on the histopathological 
result, a surgical resection of the lymphatic drainage in the form of a selective neck 
dissection could then be indicated. At present, the technical diversity and importance of 
endoscopic lymphadenectomy in the neck shows scientific and clinical potential. The 
question about the significance of the procedure, however, can not yet be answered 
conclusively. 
5. Distant metastasis 
Generally, distant metastasis is defined as tumor spread to other organ systems from its 
primary site. As a relatively rare but clinically relevant event, the development of distant 
metastasis is usually difficult to predict in clinic, especially when initial treatment planning 
is made.  
5.1 Clinicopathlological features of distant metastasis in HNSCC 
5.1.1 The incidence and common sites of distant metastasis in NHSCC  
Alavi et al. (Alavi, et al., 1999) reviewed 342 patients with mucosal HNSCC, and 47 (13.7%) 
had distant metastases. Five patients (1.5%) had metastases to infraclavicular lymph nodes 
(axilla, inguinal and presternal). The clinical detection of metastatic foci occurs in 10% to 
30% of cases, whereas autopsy studies yield an incidence of about 50% of cases with 
metastases below the clavicle (Amer, et al., 1979, Dennington, et al., 1980).  Clinical data in 
recently reported studies indicates an incidence of 4% to 23.8%, whereas autopsy data 
documents that 12% to 57% of cases had disseminated disease(Dennington, et al., 1980). 
Merino and associates (Merino, et al., 1977) in an analysis of 546 of 5019 untreated patients 
with squamous carcinoma of the upper respiratory tract who completed curative treatments, 
found clinically manifested metastases below the clavicle in 10.9% of the cases. The risk of 
subpathological distant metastases has also to be considered. New and highly sensitive 
investigations (immunohistochemistry, molecular analysis and FDG-PET/CT) and serial 
sectioning of nonregional lymph nodes and at risk organs may increase the detection of 
distant micrometastases in head and neck cancer patients. Probably the different reported 
incidence depends on the selection criteria of screening for distant metastases and the 
characteristics of the patients included (Leon, et al., 2000).  
The lungs, bones (especially the vertebrae, ribs, and skull) and the liver are the most 
common sites of hematogenous distant metastases from HNSCC (Gowen & Desuto-Nagy, 
1963). During the follow-up period after the initial treatment, 6.2% of the patients were 
diagnosed of having distant metastasis. The most common sites of distant metastasis were 
the lungs (58%) and the bones (22%). The lung is clearly the most common site of distant 
spread. The incidence of pulmonary metastases is also high in patients who present with 
extensive soft tissue extension of the primary or metastatic regional nodal disease. Holsinger 
et al, from the Anderson Cancer Center in Houston, provided a panel of clinical and 
histopathological predictors that may identify patients at the greatest risk for development 
of distant metastases in HNSCC (Holsinger, et al., 2000). In their study, the 5-year incidence 
of distant metastasis was 15.1 % (94/622). Pulmonary metastases were most commonly 
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found: 65.9% to the lung, 4.2% to the mediastinum, 2.1 % to the pleura. Metastases to bone 
(22.3%) and to the liver (9.5%) were the next most commonly encountered. Thirty (31.9%) 
patients with distant metastases presented with more than one metastatic site. Lung was the 
most common site for solitary metastasis. The most common site for bony metastasis was 
the spine (12.7%), followed by skull (4.2%), rib (3.1 %), and axial bones (femur, humerus; 2.1 
%). More than half of patients with osseous metastases presented with multiple sites. The 
patients who present with jugular vein invasion or extensive soft tissue disease in the neck 
clearly have a high incidence of pulmonary metastases. Other less common sites of 
metastases include the mediastinum, adrenal gland, brain, pericardium, kidney, and thyroid 
gland (Troell & Terris, 1995). 
5.1.2 Risk factors 
Taken into consideration to be relatively important factors in clinic, clinical T stage, N stage, 
tumor site, tumor thickness, differentiation, pattern of invasion, vascular and/or lymphatic 
invasion, bone and/or cartilage invasion, perineural invasion, and lymph nodal status have 
been reported to be associated with distant metastasis in HNSCC. However, the conclusions 
concerning the role of each independent factor differ among the various authors. In a recent 
study, we successfully demonstrated that primary tumor site, level of tumor invasion and 
numbers of levels with positive lymph node are closely related to the occurrence of distant 
metastasis in HNSCC (Li, et al., 2009). 
The incidence of metastases is influenced by T and N stage, as well as control of the primary 
lesion. As local and regional control of head and neck cancer has improved, distant 
metastases have become an increasingly common cause of death. (Vikram, et al., 1984) The 
disturbance of the lymphatic system in the cervical region resulting from radiotherapy or 
neck dissection can result in alternative pathways of lymphatic drainage. These newly 
formed pathways of drainage can ultimately result in lymphatic dissemination of head and 
neck cancers to sites below the clavicles. Metastasis from head and neck carcinomas to 
infraclavicular lymph nodes has been reported very infrequently in the literature (Nelson & 
Sisk, 1994). Recognition of this phenomenon is crucial in the evaluation of patients with 
recurrent head and neck cancer, especially when salvage surgery is entertained.  
The incidence of distant metastases is directly related to the clinical stage of the tumor, with 
high incidence of distant metastases in stage IV tumors, particularly in patients who present 
with advanced nodal disease. The distant metastasis ratio was much higher in patients with 
T3 to T4, N2 to N3 lesions who received postoperative radiotherapy. It is reported that 
locally extensive lesions T3 and T4 are most likely to metastasize and that nodal 
involvement is also associated with increased risk of distant spread. Lesions arising in the 
larynx and hypopharynx have a greater predilection to metastasize than oral lesions, 
although true vocal cord lesions infrequently metastasize as demonstrated by Snow and 
coworkers(Snow, et al., 1980).  In data of Merino (Merino, et al., 1977), 8% of all patients who 
had local control developed metastases, while 23% of those with T3 to T4 lesions had local 
control and developed distant spread. 
The incidence of pulmonary metastases is extremely high in patients who present with 
bilateral N3 disease. Disease stage showed a striking correlation with the risk for distant 
metastases (as follows): stage I, 1 %; stage II, 14%; stage III, 15%; stage IV, 20% (p < 0.0003). 
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Advanced disease (T stage> 3 and N stage> 2a) was significantly correlated statistically with 
the development of distant metastases (p < 0.003). The authors found that certain clinical 
features (extent of cervical metastasis or N stage) and histopathologic data (evidence of 
lymphatic or vascular invasion and extension beyond the confines of the lymph node) are 
associated with significantly increased rates of distant metastases.  
Spector (Spector, 2001) report a retrospective tumor registry analysis of patients with 
HNSCC of the larynx and hypopharynx who were treated with curative intent between 
January 1971 and December 1991. In 2,550 patients, the mean age, sex and tumor 
differentiation did not affect the incidence of distant metastases. The overall incidence of 
distant metastases was 8.5% (217/2,550 patients) with the following distribution: glottis 
4.4%, supraglottis 3.6%, subglottis 14%, aryepiglottic fold 16%, pyriform sinus 17% and 
posterior hypopharynx 17.6%. The overall 5-year disease-specific survival for distant 
metastases was 6.4%. Distant metastases were related to advanced local disease (T3 + T4), 
lymph node metastases at presentation (N+), tumor location (hypopharynx) and 
locoregional tumor recurrence (p =0.028). A meta-analysis of variables which predispose to 
a higher incidence of distant metastases indicate that tumor location (hypopharynx> 
larynx), advanced primary disease (T3 + T4), regional disease (N+), locoregional 
recurrences, and advanced regional metastases (N2 + N3) are statistically significant. The 
salvage rate for distant metastases was poor (6.4%) and significantly worse than the salvage 
rate for delayed regional node metastases (42%) or second primary malignancies (38%) (p = 
0.001). The onset period of distant metastases was greatest between 1.5 and 6 years post 
initial treatment with a mean of≤3.2 years. 
Research for clinicopathlological features of distant metastasis in HNSCC is of clinical 
implications in the diagnosis and treatment of the disease. Strong prognostic indicators that 
predict development of distant metastases are the presence and number of lymph node 
metastases in the neck, and extranodal spread. Once distant metastases are detected, 
patients have a very poor prognosis. The time interval between the diagnosis of distant 
metastasis and death is less than 2 years in greater than 90% of such cases.  
5.1.3 Retrograde dissemination 
Alvarez reported a retrospective study of 633 patients with HNSCC to describe the clinical 
characteristics of the distant metastasis. During the follow-up period after the initial 
treatment, 6.2% of the patients were diagnosed of having distant metastasis (Alvarez 
Marcos, et al., 2006). The site of primary tumor was hypopharynx in 14.4%, unknown origin 
in 11.8% and oropharynx in 8.5%. Three year overall survival in patients with distant 
metastasis was 2.5% (versus 49,5% in the control group).  
Nonregional lymph node dissemination should be classified as distant metastasis but 
axillary and mediastinal metastases can be part of a regional dissemination of HNSCC. 
Metastases to lymph nodes of the upper mediastinum are very common among patients 
with subglottic, hypopharynx and thyroid carcinomas. Axillary metastases are found at 
autopsy in 2–9% of the patients who died of HNSCC and are frequently associated with skin 
implantation in aggressive recurrent head and neck carcinomas. The possible explanations 
for this location of metastasis were retrograde dissemination due to lymph system blockage, 
further tumor dissemination after a parastomal recurrence, hematogenous dissemination, 
and metastasis from a second primary tumor (Kowalski, 2001).  
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5.2 Diagnose of distant metastasis in HNSCC  
5.2.1 Schemes for screening  
Because distant metastasis has an important impact on survival, early detection of this 
unfavorable status in HNSCC is substaintial for therapeutic strategy regulation. The 
metastatic workup for patients with head and neck cancer frequently includes examination 
of the cervical lymph nodes as well as chest radiography, liver function tests, and a serum 
calcium level determination. This evaluation may fail to detect metastases to distant lymph 
nodes in patients who present with recurrent or second primary cancers after previous 
therapy that has affected the cervical lymphatics. A predictable pattern of lymphatic 
metastasis based on tumor histology and site of origin has also been well documented for 
most cancers that arise in the head and neck region. 
The diagnostic and screening procedures used for distant metastasis in HNSCCs are 
sometimes equivalent and sometimes complementary. The available methods for the 
assessment of tumor status include: (1) conventional radiographs (X-rays); (2) sectional 
imaging - CT, magnetic resonance imaging (MRI), positron emission tomography (PET); (3) 
ultrasound and ultrasound-guided fine needle biopsy; (4) radionuclide scanning; (5) 
endoscopic examination and (6) histological and cytological investigations - conventional 
histology, semiserial sections, immunohistochemistry, molecular analysis and techniques of 
cell culture. 
As the lungs, bones and the liver are the most common sites of distant metastases from 
HNSCC, routine examination about these organs should be performed for high risk patients 
of metastasis in HNSCC. The prevalence of metastases at autopsy (37-57%) is much higher 
than in clinical studies (4-26%) (Leon, et al., 2000). This suggests that distant metastases in 
head and neck cancer are often asymptomatic, which raises the question of screening. Any 
investigations used for screening need to be sensitive, highly specific, inexpensive, 
noninvasive and readily available (Troell & Terris, 1995). In the absence of useful screening 
tests, metastases are usually detected by specific investigation of suspicious symptoms. 
Plain X-rays, computed tomography (CT) and bone scanning are the most frequently used 
investigations.  
Chest CT is recommended for high-risk patients, especially during the follow-up period. 
Intensified evaluation and management are mandatory for indeterminate small solitary 
pulmonary nodules because of the high rate of malignant neoplasms (Hsu, et al., 2008).  
Otherwise, cross-sectional imaging with CT and MR imaging is commonly used for tumor 
metastasis detection.  
Recently, PET using the radiotracer 18F FDG is widely used to evaluate patients with 
HNSCC. The combinated technique, PET/CT, provides anatomic and functional 
information and is useful for identification of an unknown primary tumor, detection of 
distant metastasis, establishing radiation-therapy planning, assessing therapy response, 
and long-term surveillance for recurrence. Positron emission tomography-computed 
tomography with fluorodeoxyglucose F18 (FDG-PET/CT) is widely used to evaluate 
patients with HNSCC. PET/CT can provide early, accurate detection of bone metastases 
from HNSCC and to determine the impact of detecting occult bone metastases on patient 
care. Use of FDG-PET/CT in restaging HNSCC allows for detection of occult lung, liver 
and bone metastases, and this early detection frequently influences therapeutic decision 
making (Basu, et al., 2007).  
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5.2.2 Confirmation of miscellaneous distant metastases 
5.2.2.1 Pulmonary metastasis  
Chest computed tomography (CT) scan is clearly more sensitive in identifying and 
localizing pulmonary metastasis than plain chest radiography, which can serve as a useful 
screening tool.  
Treatment of pulmonary metastases requires some evaluations concerning control of the 
primary site and regional lymph nodes, and the general physiological and mental condition 
of the patients as well as the patient's willingness to be treated. In addition, to determine the 
optimal treatment, especially when considering surgical treatment, it is necessary to exclude 
other metastases and to precisely define the sequence after the surgery. Surgical excision is 
indicated as the optimal treatment for a solitary metastasis tumor of the lung when 
chemoimmunotherapy is ineffective. The patients who have jugular vein invasion or 
extensive soft tissue encroach in the neck clearly have a high incidence of pulmonary 
metastases.  
5.2.2.2 Bone metastasis 
Because metastasis to osseous tissue is the second most common presentation of distant 
metastases, bone scan is an important and sensitive test. However, because of its non 
specificity, CT-directed needle biopsies may be necessary to establish diagnosis.  
5.2.2.3 Liver metastasis 
Hematogenous spread to liver rarely occurs without evidence of pulmonary and bone 
disease. Although liver function tests may detect abnormality, elevation in liver enzymes 
ordinarily carries low sensitivity or specificity for liver involvement. Confirmation most 
often requires a diagnostic CT scan followed by ultrasound-guided needle biopsy.  
5.2.2.4 Brain metastasis 
Brain metastasis is a rare occurrence from head and neck cancer, it is particularly more 
probable in tumor involving the temporal bone simply because of its proximity to the 
cranial vault. CT scan and magnetic resonance imaging (MRI) provide the highest sensitivity 
of screening for intracranial disease well before neurological manifestations become 
apparent.  
5.3 Management of distant metastasis in HNSCC 
5.3.1 Prevention 
It has been noted that, with the modern therapeutic regimens, the outcome of patients with 
distant metastasis from HNSCC remains dismal. Salvage therapy of metasesectomy or 
ionizing radiation is not sufficient to obtain a higher cure rate, when distant metastasis is at 
presence. It seems that optimal therapeutic strategies for distant metastasis may be adjuvant 
chemotherapy after surgery and postoperative radiotherapy at target groups of patients 
who are at high risk of developing distant metastasis. According to findings in our previous 
study (Li, et al., 2009), we propose that patients with multilevel nodal involvement in the 
neck, primary tumor localization at oropharynx, hypoparynx and larynx, and primary 
tumor invasion into muscle, bone or cartilage are at highest risk of developing distant 
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metastasis in HNSCC. Therefore, these subsets of patients with high risk factors should be 
considered for a more through evaluation for detecting distant metastasis and a more 
increasing utilization of adjuvant chemotherapy for preventing distant metastasis. However, 
it must be mentioned that screening for distant metastasis in the follow-up doses little help 
in improving the outcome, since there is mostly no possibility of a curative intervention.  
5.3.2 Surgery 
Treatment of metastases is generally difficult. The difficulty seems to be caused by the low 
sensitivity of metastatic tumor cells to anticancer drugs and radiation. Surgery and 
radiotherapy are the main treatment modality of morning metastases for HNSCC. 
Metastasized regional lymph nodes are usually controlled by surgical removal (Shah & 
Andersen, 1994). However, surgical removal of distant metastatic tumors is usually not 
easy, especially in patients with multiple organ metastases. Because of these difficulties in 
conservative and surgical treatments, distant metastases are lethal in most patients. 
Treatment planning for cases with axillary metastasis must take in consideration the 
likelihood of other regional recurrences and/or distant metastasis. Also, the presence of a 
second primary tumor must be ruled out. Whenever axilla is the only site of cancer 
recurrence, a standard axillary dissection must be considered. Upper mediastinal metastases 
from subglottic and hypopharyngeal cancer are managed by paratracheal and mediastinal 
dissection through the neck and postoperative radiotherapy (Kowalski, 2001).  
Surgery is sometimes useful in the treatment of bone metastases. For example, pulmonary 
metastasectomy of isolated metastasis has been shown to be of benefit in selected patients 
(Wedman, et al., 1996). Surgery is sometimes useful in the treatment of bone metastases, 
although radiotherapy is the standard first-line treatment. In metastatic brain tumor, 
surgical resection should also be considered for patients with solitary brain metastasis and 
no extracranial disease or controlled extracranial disease. Whole-brain radiotherapy is 
routinely administered postoperatively (Hoegler, 1997). Although surgical removal of 
isolated solid metastatic tumors in liver is sometime carried out, adjuvant chemoradiation is 
the mainstream in the treatment modalities. 
Occasionally, surgical resection of metastases is useful for metastases that do not respond to 
radiotherapy and in weight-bearing or high-stress areas (subtrochanteric region of the hip, 
mid-femoral diaphysis, mid-humeral metaphysis). Surgical stabilization can improve the 
remaining quality of life in these patients if it is carried out early enough (Sim, et al., 1992). 
A brief, fractionated course of radiotherapy is usually given postoperatively (Hoegler, 1997). 
5.3.3 Chemotherapy 
Head and neck cancer metastases are responsive to chemotherapy and the use of multiple 
agents may increase response rate. Unfortunately, neither single agent nor combinations of 
drugs have any significant impact on survival (de Mulder, 1999). The exception may be 
nasopharyngeal carcinoma, where platinum-based chemotherapy may increase survival 
even in the presence of distant metastases (Gebbia, et al., 1993). Chemotherapy also acting as 
a radiosensitizer, increases survival in advanced metastasis in HNSCC. 
Neoadjuvant chemotherapy with the cisplatin and fluororacil (PF) regimen in HNSCC 
patients has no effect on locoregional relapse. However, it shows a small but significant 
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benefit in reducing distant metastasis and improving the overall survival (Su, et al., 2008). 
Many new chemotherapy ways are attempted in a broader sense of targeted therapy.  
Multi-modality treatment or targeted therapy-containing management does not significantly 
improve overall survival.  
Systemic chemotherapy management of extensive metastasis in HNSCC patients is a major 
concern. The drugs most commonly used clinically are the platin compounds (cisplatin and 
carboplatin), taxanes (docetaxel and paclitaxel), 5-FU, methotrexate, and ifosfamide. In an 
effort to improve response rates and, hopefully, survival time, combination chemotherapy 
needs to be developed.  
5.3.4 Radiotherapy 
Radiotherapy is the standard first-line treatment of bone metastases in HNSCC. 
Radiotherapy also has a role in the infrequent patients with brain metastases, especially for 
solitary brain metastasis with no extracranial diseases or have been controlled. It relieves 
clinical symptoms in 70-90% of patients (Hoegler, 1997). The use of stereotactic radiosurgical 
treatment remains to be defined. It is most often used to treat solitary metastases in 
previously irradiated patients. 
Radiotherapy is unlikely to cure even solitary lung metastases. However, it may have a 
palliative role and increase survival when there are a limited number of foci, small 
metastases and locoregional control (Sugawara & Kaneta, 1983). Approximately 50% of 
patients with cancer develop bone metastases, although they are relatively unusual in head 
and neck cancer. They can cause pain and affect weight-bearing areas and consequently 
have a significant impact on quality of life. The role of radiotherapy in the palliation of bone 
metastases is well supported in the literature, with reported response rates of around 70-
90% (Arcangeli, et al., 1998, Hoegler, 1997). The pain relief is complete in nearly half of the 
responders (Uppelschoten, et al., 1995) (Steenland, et al., 1999). If patients fail to respond to 
the first treatment, then they may respond to re-treatment. 
5.3.5 Associated targeting therapy 
Recently, molecular targeting biologicals with a different toxicity profile and hopefully less 
late damage to functionally important tissues may open new strategies in primary and 
adjuvant treatment of HNSCC. The principal strategies currently being used to design 
antiangiogenesis agents are aimed at blocking angiogenic factors (or enhancing negative 
regulators) or acting on endothelial cells to block cell surface receptors or prevent them from 
breaking down the surrounding matrix.  
Besides cetuximab and other EGFR targeting mAbs, there are other receptors and non-
receptor tyrosine kinase inhibitors, which might play an important role in the future 
treatment of HNSCC. Many investigatons have been carried out to solve the problem of 
multi-drug resistance in HNSCC progenitor cells. Cetuximab, as an epidermal growth 
factor receptor-specific monoclonal antibody, plus radiation were shown to improve 
survival rate as compared to radiation treatment alone (Bonner, et al., 2006). However, 
one retrospective study suggests the duration of progression free survival and overall 
survival is shorter in patient receiving cetuximab plus radiation than those with cisplatin 
plus radiation (Pignon, et al., 2009). 
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It is prostulated that VEGF targeted therapy has the potential to fulfill both anti-angiogenic 
and anti-tumorigenic functions (Tong, et al., 2008). As reported, CD44 certainly posseses a 
valid target for anti-cancer therapy. CD44 targeting members of several relevant pathways 
might be used to induce apoptosis or inhibit tumour angiogenesis and metastatic spread. 
Immunotherapy for HNSCC is a relatively new but promising therapeutic strategy. In 
HNSCC, immunotherapy has been implemented successfully in patients, especially in 
patients with end-stage metastasising disease, who had undergone a variety of other 
therapeutic modalities. Despite this fact, both clinical and translational trials with cytokines, 
monoclonal antibodies, and various kinds of other strategies have yielded promising results 
with little evidence of host toxicity. Future efforts will be foucusing on finding ways to 
circumvent immune tolerance and overcome malignancy-related immune dysfunction to 
produce regimens with better efficacy. 
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